Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever

International Journal of Infectious Diseases

Volumn 15, Issue 1, 2011, Pages

  Bodur, Hürrem ^a   Erbay, Ayşe ^a   Akinci, Esragül ^a   Öngürü, Pinar ^a   Bayazit, Nurhayat ^a   Eren, Selim Sirri ^a   Kubar, Ayhan ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Hemorrhagic fever; Ribavirin; Virus

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; RIBAVIRIN;

ADULT; ARTICLE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DISEASE COURSE; FATALITY; FEMALE; HEMATOLOGY; HUMAN; MALE; THROMBOCYTE COUNT; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 78650888643     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.09.009     Document Type: Article

References (20)

1. Whitehouse C.A. Crimean-Congo hemorrhagic fever. Antivir Res 2004, 64:145-160.
2. Andersson I., Bladh L., Mousavi-Jazi M., Magnusson K.E., Lundkvist A., Haller O., et al. Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J Virol 2004, 78:4323-4329.
3. World Health Organization. Crimean-Congo haemorrhagic fever. Geneva: World Health Organization; November 2001. Available at: (accessed July 20, 2008). http://www.who.int/mediacentre/factsheets/fs208/en/.
4. Cevik M.A., Erbay A., Bodur H., Gülderen E., Baştuĝ A., Kubar A., et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 2008, 12:374-379.
5. Bakir M., Ugurlu M., Dokuzoguz B., Bodur H., Tasyaran M.A., Vahaboglu H., et al. Crimean-Congo hemorrhagic fever outbreak in Middle Anatolia: a multicenter study of clinical features and outcome measures. J Med Microbiol 2005, 54:1-5.
6. Reports of the Communicable Diseases Department of the Ministry of Health of Turkey [in Turkish]. Ankara, Turkey: Ministry of Health of Turkey; 2008. Available at: (accessed July 20, 2008). http://www.kirim-kongo.saglik.gov.tr/.
7. World Health Organization. Ribavirin. Geneva: World Health Organization; 2008. Available at: http://www.who.int/emlib/MedicineDisplay.aspx?Language=EN&MedIDName=459%40ribavirin (accessed July 20, 2008).
8. Watts D.M., Ussery M.A., Nash D., Peters C.J. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 1989, 41:581-585.
9. Tignor G.H., Hanham C.A. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res 1993, 22:309-325.
10. Ozkurt Z., Kiki I., Erol S., Erdem F., Yilmaz N., Parlak M., et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006, 52:207-215.
11. Mardani M., Jahromi M.K., Naieni K.H., Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003, 36:1613-1618.
12. Duh D., Saksida A., Petrovec M., Ahmeti S., Dedushaj I., Panning M., et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg Infect Dis 2007, 13:1769-1772.
13. Cevik M.A., Erbay A., Bodur H., Eren S.S., Akinci E., Sener K., et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis 2007, 45:e96-100.
14. Yapar M., Aydogan H., Pahsa A., Besirbellioglu B.A., Bodur H., Basustaoglu A.C., et al. Rapid and quantitative detection of Crimean-Congo hemorrhagic fever virus by one-step real-time reverse-transcriptase PCR. Jpn J Infect Dis 2005, 58:358-362.
15. Ergonul O., Celikbas A., Dokuzoguz B., Eren S., Baykam N., Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004, 39:285-287.
16. Sheikh A.S., Sheikh A.A., Sheikh N.S., Rafi-U-Shan, Asif M., Afridi F., et al. Bi-annual surge of Crimean-Congo haemorrhagic fever (CCHF): a five-year experience. Int J Infect Dis 2005, 9:37-42.
17. Jabbari A., Besharat S., Abbasi A., Moradi A., Kalavi K. Crimean-Congo hemorrhagic fever: case series from a medical center in Golestan province, Northeast of Iran (2004). Indian J Med Sci 2006, 60:327-329.
18. Leyssen P., De Clercq E., Neyts J. Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 2008, 78:9-25.
19. Bray M. Highly pathogenic RNA viral infections: challenges for antiviral research. Antiviral Res 2008, 78:1-8.
20. Wolfel R., Paweska J.T., Petersen N., Grobbelaar A.A., Leman P.A., Hewson R., et al. Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients. Emerg Infect Dis 2007, 13:1097-1100.